Lung Cancer Trials Ask AI to find trials
TerminatedNot applicableNCT03400748
Official study title

ANET Electrosurgery Applicator Pilot Evaluation Study

Study summary

Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.

Ask AI to explain this study
Start here

Key things to know

Main goalDevice Feasibility

This describes the study’s primary purpose.

What is being studiedRF Ablation

The study team can explain what participation involves.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Apr 3, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?4 U.S. locations

Locations may change over time.

Who runs it?Olympus Corporation of the Americas

Study sponsor

01
Study overview

What this study is about

Purpose
Device Feasibility
Study type
Interventional
Phase
Not applicable
Sponsor
Olympus Corporation of the Americas
Interventions being studied
Device: RF Ablation
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting
Metastatic or stage IV→
Treatment approach
Surgery→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Subject with Stage I or Stage II primary lung cancer or metastatic lung tumor 2. Pathological proof of target nodule/tumor type and malignancy 3. Target nodule/tumor which can be accessed via EBUS bronchoscopy 4. Resection/surgical candidate 5. Participants must be at least 18 years old and able to provide consent

Reasons someone may not be able to joinExclusion criteria

1. Subjects in whom flexible bronchoscopy is contraindicated 2. Target nodule \< 1.0 cm 3. Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor 4. Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives 5. Pacemaker, implantable cardioverter, or other electronic implantable device

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Beth Israel Deaconess Medical CenterBoston, Massachusetts
  • Duke University Medical CenterDurham, North Carolina
  • UT MD Anderson Cancer CenterHouston, Texas
  • Toronto General HospitalToronto, Ontario

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 3, 2024. Always confirm current availability with the study team.

View original record ↗